Early outcomes of switching from bevacizumab to aflibercept-jbvf in exudative macular diseases: a real-world study. Horozoglu Ceran T, Beyatli S, Dogan M. BMC Ophthalmol 2026;26:702.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Horozoglu Ceran T, Beyatli S, Dogan M. Early outcomes of switching from bevacizumab to aflibercept-jbvf in exudative macular diseases: a real-world study. BMC Ophthalmol 2026;26:702.
PMID: 42958502